October 22, 2014

FERRING PHARMACEUTICALS TO ACQUIRE MARKETING RIGHTS FOR DDAVP® (DESMOPRESSIN) PRODUCT PORTFOLIO FROM SANOFI

PARSIPPANY, N.J., Oct. 22, 2014 /PRNewswire-USNewswire/ – Ferring Pharmaceuticals is pleased to announce that the company has acquired DDAVP® (desmopressin acetate) from Sanofi. Ferring is the original developer of the drug desmopressin and has a long-standing history in peptide-based specialty care.

“The return of DDAVP to its roots at Ferring is a welcome addition to our portfolio of products and affirms our commitment to supporting a wide range of disorders with high unmet medical need,” said Aaron Graff, President & COO, Ferring Pharmaceuticals Inc. “As a result of this acquisition, distribution of DDAVP will be transferred from Sanofi to Ferring immediately.”

DDAVP is available in the following formulations: DDAVP® Tablets, DDAVP® Nasal Spray, DDAVP® Rhinal Tube and DDAVP® Injection.

About DDAVP®
Ferring has a long-standing interest in the area of endocrinology and pediatric urology, which began with the development of desmopressin (desmopressin acetate) in the mid-1970s.

All desmopressin formulations (DDAVP® Tablets, DDAVP® Nasal Spray, DDAVP® Rhinal Tube, and DDAVP® Injection) are approved by the U.S. Food and Drug Administration (FDA).

You are encouraged to report side effects of prescription drugs. Contact Ferring at 1-888-FERRING (1-888-337-7464) or call 1-800-FDA-1088 or visit www.fda.gov/medwatch.

About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopaedics, and urology. For more information, call 1-888-FERRING (1-888-337-7464); visit www.FerringUSA.com.

© 2014 Ferring B.V.

GC/1652/2014/US

This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

All information on this site is intended for US audiences only.

CERVIDIL, CLENPIQ, ENDOMETRIN, EUFLEXXA, FIRMAGON, MENOPUR, NOCDURNA, NOVAREL, and ZOMACTON are registered trademarks of Ferring B.V. INVOCELL is a registered trademark of INVO BioScience. ORTIKOS is a trademark of Sun Pharma Global FZE.

©2008-2020 Ferring Pharmaceuticals.  US-CORP-2000031